The Pradaxa label was revised and updated several times as seen in the first link you've posted "Label and Approval History". Your secound link is indeed the most recent update (Revised: 11/2012), after FDA’s study of the bleeding issue. My reply to Clark points to an earlier revision and update on the need to assess and monitor renal function and lower dose if required.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.